2012|13 Annual Report Fraunhofer IGB

69 A B C Dr. Martin Funk Phone +49 711 970-4093 martin.funk@igb.fraunhofer.de Prof. Dr. Heike Walles Phone +49 711 970-4117 heike.walles@igb.fraunhofer.de Funding We would like to thank the German Federal Ministry of Educa- tion and Research (BMBF) for funding the project “Reconstruc- tion of bioartiﬁcial tissue for tracheal surgery”, promotional refer- ence FKZ0315575. Project partners Robert Bosch Hospital Schillerhöhe, Gerlingen | Orgenesis Inc., White Plains, NY, USA patients must take years of immunosuppressive drugs. In ad- dition, the ﬁrst clinical trial data have shown that such trans- plants are only functional for 3–5 years. Orgenesis has established a technology that allows the devel- opment of the patient’s own liver cells into functional insulin- producing cells. In the process, a biopsy of liver cells are taken from the patient, expanded in the laboratory, and then genet- ically programmed so that they are of a similar phenotype of the cells from the islets of Langerhans, which produce insulin. Such a transplant would not be attacked by the patient’s im- mune system. 1 Incubator wagon and bioreactors for producing implants. 2 C-area of the GMP unit at the Fraunhofer IGB. 3 (A) BioVaSc, (B) muscle cells (C) endothelial cells. 4 Microvascular endothelial cells imaged by ﬂuorescent LDL. 3 4 Contacts

2012|13 Annual Report Fraunhofer IGB

Pages